Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$798.99 USD

798.99
1,216,922

-7.15 (-0.89%)

Updated Nov 5, 2024 11:52 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Nilanjan Banerjee headshot

Fight Off the Coronavirus Blues With 5 Low-Beta Stocks

It is an ideal time to invest in low-beta stocks since they might provide a shield against coronavirus-induced market volatility.

Sweta Jaiswal, FRM headshot

Biotech ETFs to Gain From Latest Advancements in Cancer Drugs

The rising incidence of cancer cases has encouraged several major pharmaceutical and biotech players to invest substantially in the developments of drugs.

Phibro (PAHC) Q3 Earnings Surpass Estimates, Margin Declines

Phibro (PAHC) witnessed revenue uptick in its core Animal Health segment in Q3 despite the coronavirus-led business disruptions in the animal production industry.

HMS Holdings (HMSY) Earnings and Revenues Beat Estimates in Q1

HMS Holdings (HMSY) witnessed revenue growth at COB and PI segments in Q1.

Kinjel Shah headshot

Drug Sector Highly Resilient Amid Coronavirus Mayhem: 5 Picks

Here we highlight five large drugmakers that can be added to one's portfolio amid the coronavirus crisis.

Allscripts (MDRX) Q1 Earnings and Revenues Miss Estimates

Allscripts (MDRX) witnessed a decline in core Client Services and Software delivery unit revenues in Q1.

National Vision (EYE) Q1 Earnings Top Estimates, Margin Falls

National Vision's (EYE) first-quarter 2020 results were better than expected despite the coronavirus-led economic crisis.

Integer Holdings (ITGR) Q1 Earnings & Revenues Top Estimates

Integer Holdings' (ITGR) first-quarter results benefit from strength in Cardio & Vascular sub-segment and margin expansion.

ESG Stocks Remain Resilient to Virus Slump: 5 Top Picks

ESG stocks bear lesser financial risk due to their focus on environment, employees and supply chain. Investment in these companies can return well.

Zimmer Biomet (ZBH) Q1 Earnings Top, Revenues Miss Estimates

The spread of coronavirus results in deferral of elective procedures for Zimmer Biomet (ZBH) in Q1.

Insulet (PODD) Q1 Earnings Lag Estimates, Margins Decline

Insulet's (PODD) first-quarter 2020 results reflect mixed segmental performance amid the coronavirus-led economic crisis.

Fresenius Medical (FMS) Q1 Earnings Miss Estimates, Fall Y/Y

Fresenius Medical's (FMS) first-quarter earnings benefit from strong segmental performance.

Cardinal Health (CAH) Beats Q3 Earnings and Revenue Estimates

Cardinal Health's (CAH) fiscal third-quarter results benefit from strong segmental performance.

LHC Group (LHCG) Earnings and Revenues Beat Estimates in Q1

LHC Group (LHCG) continues to gain from home health services and hospice admissions, which improved year over year in Q1.

Radius' (RDUS) Q1 Earnings Miss Estimates, Sales Surpass

Radius (RDUS) reports wider-than-expected loss but beats sales estimates in the first quarter. The company lowers guidance for 2020.

Kinjel Shah headshot

Pharma Stock Roundup: Q1 Earnings of BMY, NVO, Coronavirus Update From PFE, RHHBY

Novo Nordisk (NVO) and Bristol-Myers (BMY) announce Q1 results. Pfizer (PFE), Roche (RHHBY) and Lilly (LLY) provide update on their coronavirus-related research efforts.

OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates

OPKO Health's (OPK) first-quarter results benefit from increase in RAYALDEE prescriptions.

Globus Medical (GMED) Misses on Q1 Earnings and Revenues

Globus Medical (GMED) witnesses around $20 million of COVID-19 related adverse impact on its Q1 sales.

Omnicell (OMCL) Q1 Earnings Top, Operating Margin Rises

Omnicell's (OMCL) Q1 revenues suffer due to slowdown in hospital purchasing decisions and product bookings.

Avanos Medical (AVNS) Q1 Earnings Lag Estimates, Revenues Top

Avanos Medical's (AVNS) first-quarter results benefit from segmental contribution.

DENTSPLY SIRONA (XRAY) Posts Weak Q1 Preliminary Results

DENTSPLY SIRONA's (XRAY) first-quarter 2020 preliminary results reflect weak segmental performance and decline in revenues.

Integra (IART) Lags Q1 Earnings Estimates, Withdraws Outlook

Integra's (IART) first-quarter 2020 results reflect disappointing segmental performance due to coronavirus-led business disruptions.

Glaukos (GKOS) Q1 Earnings and Revenues Miss Estimates

Glaukos (GKOS) witnessed a contraction in gross margin but year-over-year revenue surge in Q1.

Bruker (BRKR) Q1 Earnings Miss Estimates, Guidance Suspended

Bruker's (BRKR) first-quarter 2020 results reflect dismal performance by all segments and geographies due to coronavirus-led business disruptions.

Pacific Biosciences (PACB) Q1 Earnings Surpass Estimates

Pacific Biosciences (PACB) saw revenue growth in the Service and Other segment in Q1.